185 related articles for article (PubMed ID: 38036156)
1. Treatment of acral and mucosal melanoma: Current and emerging targeted therapies.
Zhang J; Tian H; Mao L; Si L
Crit Rev Oncol Hematol; 2024 Jan; 193():104221. PubMed ID: 38036156
[TBL] [Abstract][Full Text] [Related]
2. Management of Acral and Mucosal Melanoma: Medical Oncology Perspective.
Jung S; Johnson DB
Oncologist; 2022 Aug; 27(8):703-710. PubMed ID: 35640549
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.
Mao L; Qi Z; Zhang L; Guo J; Si L
Front Immunol; 2021; 12():680407. PubMed ID: 34149718
[TBL] [Abstract][Full Text] [Related]
4. Molecular Markers and Targets in Melanoma.
Teixido C; Castillo P; Martinez-Vila C; Arance A; Alos L
Cells; 2021 Sep; 10(9):. PubMed ID: 34571969
[TBL] [Abstract][Full Text] [Related]
5.
Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
[TBL] [Abstract][Full Text] [Related]
6. Advanced Acral Melanoma Therapies: Current Status and Future Directions.
Zhang Y; Lan S; Wu D
Curr Treat Options Oncol; 2022 Oct; 23(10):1405-1427. PubMed ID: 36125617
[TBL] [Abstract][Full Text] [Related]
7. Targeted Genomic Profiling of Acral Melanoma.
Yeh I; Jorgenson E; Shen L; Xu M; North JP; Shain AH; Reuss D; Wu H; Robinson WA; Olshen A; von Deimling A; Kwok PY; Bastian BC; Asgari MM
J Natl Cancer Inst; 2019 Oct; 111(10):1068-1077. PubMed ID: 30657954
[TBL] [Abstract][Full Text] [Related]
8. Targeted Therapy and Immunotherapy for Melanoma in Japan.
Namikawa K; Yamazaki N
Curr Treat Options Oncol; 2019 Jan; 20(1):7. PubMed ID: 30675668
[TBL] [Abstract][Full Text] [Related]
9. Genetic characteristics and response to systemic therapies of acral lentiginous melanoma at a tertiary care center-a retrospective review.
Jamerson T; Rebecca VW; Aguh C
J Natl Med Assoc; 2022 Feb; 114(1):7-11. PubMed ID: 34509302
[TBL] [Abstract][Full Text] [Related]
10. Melanoma genomics: a state-of-the-art review of practical clinical applications.
Guhan S; Klebanov N; Tsao H
Br J Dermatol; 2021 Aug; 185(2):272-281. PubMed ID: 34096042
[TBL] [Abstract][Full Text] [Related]
11. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.
Steeb T; Wessely A; Petzold A; Kohl C; Erdmann M; Berking C; Heppt MV
Eur J Cancer; 2021 Nov; 157():348-357. PubMed ID: 34562816
[TBL] [Abstract][Full Text] [Related]
12. KIT gene mutations and copy number in melanoma subtypes.
Beadling C; Jacobson-Dunlop E; Hodi FS; Le C; Warrick A; Patterson J; Town A; Harlow A; Cruz F; Azar S; Rubin BP; Muller S; West R; Heinrich MC; Corless CL
Clin Cancer Res; 2008 Nov; 14(21):6821-8. PubMed ID: 18980976
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma.
Kiniwa Y; Okuyama R
Jpn J Clin Oncol; 2021 Mar; 51(3):315-320. PubMed ID: 33338202
[TBL] [Abstract][Full Text] [Related]
14. Update on the targeted therapy of melanoma.
Johnson DB; Sosman JA
Curr Treat Options Oncol; 2013 Jun; 14(2):280-92. PubMed ID: 23420410
[TBL] [Abstract][Full Text] [Related]
15. Genomic Landscapes of Acral Melanomas in East Asia.
Chang JW; Hsieh JJ; Wu CE; Lim AH; Ng CC; Teh BT; Chan JY
Cancer Genomics Proteomics; 2021; 18(1):83-92. PubMed ID: 33419898
[TBL] [Abstract][Full Text] [Related]
16. Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.
Larkin J; Marais R; Porta N; Gonzalez de Castro D; Parsons L; Messiou C; Stamp G; Thompson L; Edmonds K; Sarker S; Banerji J; Lorigan P; Evans TRJ; Corrie P; Marshall E; Middleton MR; Nathan P; Nicholson S; Ottensmeier C; Plummer R; Bliss J; Valpione S; Turajlic S
Cell Rep Med; 2024 Mar; 5(3):101435. PubMed ID: 38417447
[TBL] [Abstract][Full Text] [Related]
17. KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development.
Meng D; Carvajal RD
Am J Clin Dermatol; 2019 Jun; 20(3):315-323. PubMed ID: 30707374
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma.
Delyon J; Lebbe C; Dumaz N
Curr Opin Oncol; 2020 Mar; 32(2):79-84. PubMed ID: 31833955
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.
Ogata D; Haydu LE; Glitza IC; Patel SP; Tawbi HA; McQuade JL; Diab A; Ekmekcioglu S; Wong MK; Davies MA; Amaria RN
Cancer Med; 2021 Apr; 10(7):2293-2299. PubMed ID: 33686688
[TBL] [Abstract][Full Text] [Related]
20. [ Spectrum of oncogene mutations is different in melanoma subtypes].
Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
